Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.
Understanding the mechanisms of HIV-1 drug resistance is critical for developing more effective antiretroviral agents and therapies. Based on our previously described dynamic copy-choice mechanism for retroviral recombination and our observations that nucleoside reverse transcriptase inhibitors (NRTIs) increase the frequency of reverse transcriptase template switching, we propose that an equilibrium exists between (i) NRTI incorporation, NRTI excision, and resumption of DNA synthesis and (ii) degradation of the RNA template by RNase H activity, leading to dissociation of the template-primer and abrogation of HIV-1 replication. As predicted by this model, mutations in the RNase H domain that reduced the rate of RNA degradation conferred high-level resistance to 3'-azido-3'-deoxythymidine and 2,3-didehydro-2,3-dideoxythymidine by as much as 180- and 10-fold, respectively, by increasing the time available for excision of incorporated NRTIs from terminated primers. These results provide insights into the mechanism by which NRTIs inhibit HIV-1 replication and imply that mutations in RNase H could significantly contribute to drug resistance either alone or in combination with NRTI-resistance mutations in reverse transcriptase.
Nikolenko
Galina N
GN
Viral Mutation Section, HIV Drug Resistance Program, National Cancer Institute, Frederick, MD 21702, USA.
Palmer
Sarah
S
Maldarelli
Frank
F
Mellors
John W
JW
Coffin
John M
JM
Pathak
Vinay K
VK
D000998:Antiviral Agents / Q000378:metabolism; D002460:Cell Line; D004260:DNA Repair; D024882:Drug Resistance, Viral; D015497:HIV-1 / Q000187:drug effects / Q000201:enzymology / Q000235:genetics / Q000502:physiology*; D006801:Humans; D009705:Nucleosides / Q000737:chemistry* / Q000378:metabolism; D011995:Recombination, Genetic; D018894:Reverse Transcriptase Inhibitors / Q000378:metabolism; D016914:Ribonuclease H / Q000378:metabolism*; D014779:Virus Replication; D015215:Zidovudine / Q000494:pharmacology
D000998:Antiviral Agents; D009705:Nucleosides; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D016914:Ribonuclease H